In the presence of a selective ERK1/2 inhibitor, FR180204, we observed a dose-dependent reduction at the transcript levels of Snail/Twist1 in oral cancer cells (Figure 4C). This evidence concerns the gene TWIST1 and lip and oral cavity carcinoma.